In this episode, the faculty will review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate will also extend to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.
Faculty: Debbie Shawcross (Moderator), Rajiv Jalan (Faculty), Sara Montagnese (Faculty), Elliot Tapper (Faculty)
This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).
Related episodes:
- EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?
- EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
- EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
- EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within
- EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?
- EASL Studio S2E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?